RENBP and prostate carcinoma: For menopause, the main pathways included pathways in cancer, lipid and atherosclerosis, chemical carcinogenesis-receptor activation, prostate cancer, EGFR tyrosine kinase inhibitor resistance, neuroactive ligand-receptor interaction, AGE-RAGE signaling pathway in diabetic complications, hepatitis B, PI3K-Akt signaling pathway, and HIF-1 signaling pathway (Figure 4H).